UNVERIFIEDSingle Source
Stocks making the biggest moves premarket: Bumble, Hims & Hers Health, Blue Owl, Netskope & more
CNBC|3/12/2026
H
Hims
28 stories tracked
Executive summary being generated...
Lindy
0
Breaking
0
Unverified
14
Activity (Last 30 Days)
2
1
1
2026-03-092026-03-12
Top Publishers
CNBC8 stories
Reuters3 stories
Financial Times2 stories
Stat News1 stories
Stories (Latest First)
UNVERIFIEDSingle Source
Stocks making the biggest moves midday: Rivian, Hims & Hers, BioNTech, Vertex Pharmaceuticals & more
CNBC|3/10/2026
UNVERIFIEDSingle Source
Stocks making the biggest moves midday: Chevron, Hims and Hers, Xenon Pharma, Vertiv and more
CNBC|3/9/2026
UNVERIFIEDSingle Source
Stocks making the biggest moves premarket: Hims & Hers Health, oil stocks, Live Nation Entertainment & more
CNBC|3/9/2026
UNVERIFIEDSingle Source
Stocks making the biggest moves premarket: AMD, Home Depot, Hims & Hers Health, Diamondback Energy and more
CNBC|2/24/2026
UNVERIFIEDSingle Source
Stocks making the biggest moves premarket: Walmart, Hims & Hers, Carvana, Figma & more
CNBC|2/19/2026
UNVERIFIEDSingle Source
Hims & Hers is a brave bet on solving the disruptor’s dilemma
Financial Times|2/15/2026
UNVERIFIEDSingle Source
Stocks making the biggest moves midday: Oracle, Cleveland-Cliffs, Nexstar, Workday, Hims & Hers
CNBC|2/9/2026
UNVERIFIEDSingle Source
Stocks making the biggest moves premarket: Oracle, Novo Nordisk, Hims & Hers Health, Kroger and more
CNBC|2/9/2026
UNVERIFIEDSingle Source
Hims & Hers abandons copycat weight-loss drug in face of FDA probe
Financial Times|2/7/2026
UNVERIFIEDSingle Source
HHS asks Justice Department to probe Hims & Hers over its cheaper compounded version of Wegovy - statnews.com
Stat News|2/7/2026
UNVERIFIEDSingle Source
US signals crackdown on compounded weight-loss drugs; Hims shares tumble
Reuters|2/6/2026
UNVERIFIEDSingle Source
Hims & Hers' $49 weight-loss pill jolts everyone, except its stock
Reuters|2/6/2026
UNVERIFIEDSingle Source
Hims offers cheapest GLP-1 weight-loss pill in US in a shock to Novo, Lilly
Reuters|2/5/2026